|
Patent landscape, scope, and claims summary: |
Patent Landscape Analysis: US 10,086,046 (hIL-2 mutein expanded Treg therapy for autoimmune disease)
US 10,086,046 claims an ex vivo cell-processing and adoptive transfer regimen that uses PBMCs expanded into a regulatory T cell (Treg) enriched population by contact with a human interleukin-2 (hIL-2) mutein containing specific amino-acid substitutions at positions 20, 88, and/or 126 (per SEQ ID NO:1). The method is directed at autoimmune diseases including type I diabetes, multiple sclerosis, and systemic lupus erythematosus (SLE). The claim set also provides narrower composition/variant coverage for specific substitutions (e.g., N88R, N88G, N88I; D20H, D20I, D20Y; Q126L) and adds optional combination with standard immunosuppressants.
What do the claims actually require, element by element?
Independent claim 1: ex vivo contact, Treg induction, and adoptive transfer
Claim 1 is a “process of treatment” with three core technical steps:
- Source material
- “Peripheral mononuclear blood cells (PBMCs) derived from a first organism”
- Key biological driver (hIL-2 mutein with position constraint)
- “contacting” PBMCs with a “mutein of human interleukin-2 (hIL-2 mutein)”
- the mutein must have “an amino acid substitution in at least one of the positions 20, 88, or 126” numbered against the hIL-2 wild-type sequence in SEQ ID NO: 1
- the contact must be to “obtain a cell population which comprises regulatory T cells”
- Delivery and indication
- “introducing the cell population into a second organism”
- treating “autoimmune disease” limited to: type I diabetes, multiple sclerosis, and SLE
Dependent claims tighten the IL-2 mutein definition
- Claim 2: first and second organisms are the same or same species (self-administration and homologous transfer framing).
- Claim 3: specifies position 88: N88R, N88G, or N88I.
- Claim 4: allows “at least one further amino acid substitution” in any other position, but requires it be conservative.
- Claim 5: specifies position 20: D20H, D20I, or D20Y.
Note the claim text includes a likely typographical anomaly (“D200”) that, if uncorrected in prosecution/interpretation, can affect scope.
- Claim 6: specifies position 126: Q126L.
- Claim 7: optional regimen adds “administering … an immunosuppressant.”
- Claim 8: lists a broad immunosuppressant menu, covering corticosteroids, classic immunosuppressants, calcineurin inhibitors, antiproliferatives, mTOR inhibitors, kinase inhibitors, anti-T cell therapies, anti-CD25, and multiple biologics (including anti-TNF agents).
Scope consequence: claim 1 is broad on “at least one position,” narrow on “Treg outcome”
Claim 1 does not require a particular single substitution identity at 20, 88, or 126 beyond “an amino acid substitution.” It does require the functional outcome: the cell population “comprises regulatory T cells.” This creates two major claim-construction pressure points:
- Variant breadth: Any substitution at 20 or 88 or 126 could fall within claim 1, but claims 3/5/6 narrow the conventional “commercially legible” sub-variants.
- Outcome boundary: “comprises regulatory T cells” is less exact than “CD4+CD25+FOXP3+” type gating, but it still anchors infringement to a Treg-containing product.
What is new or defensible about the claimed IL-2 mutein approach?
Position-based IL-2 muteins for biased Treg biology
The claim architecture tracks a known strategy in IL-2 therapeutics: modifying IL-2 to preferentially expand or support Tregs over effector T cells through receptor signaling bias. The patent’s novelty is anchored to:
- using IL-2 mutein(s) with substitutions at positions 20, 88, and/or 126 (per SEQ ID NO:1 numbering)
- applying that mutein ex vivo to PBMCs to generate a Treg-enriched cell population
- then performing adoptive transfer to treat autoimmune diseases
Critical observation on defensibility
The defensibility is less about “adoptive Treg therapy” per se and more about the combination of:
- ex vivo PBMC contact with specific IL-2 mutein variants, and
- treatment of specified autoimmune indications via reinfusion of the resulting cell population.
If the underlying prior art already discloses ex vivo Treg generation using IL-2 variants, then infringement reduces to whether the prior art includes substitutions at the claimed positions with the same numbering scheme and functional Treg readout.
Where does the claim landscape face prior-art pressure?
1) Ex vivo Treg induction using IL-2 has extensive disclosure history
Adoptive Treg therapy has long used IL-2, including ex vivo stimulation and expansion workflows in autoimmune settings. The landscape pressure concentrates on whether prior documents used:
- human IL-2 muteins rather than wild-type IL-2, and
- IL-2 mutein substitutions at 20/88/126 with the same sequence numbering, and
- whether the documents target the same autoimmune indications.
2) IL-2 muteins with receptor-biased variants are known, but “position identity” is the gating issue
Many IL-2 engineering programs target select residues to bias receptor engagement (e.g., reduced CD122/effector signaling or enhanced CD25/Treg bias). For infringement under claim 1, the mutein must have substitutions at at least one of the three claimed positions. That means:
- If prior art discloses a mutein with substitutions at unrelated positions, it may avoid claim 1.
- If prior art discloses substitutions at the same positions but in a different sequence numbering scheme, litigation depends on the mapping to SEQ ID NO:1.
3) The optional immunosuppressant add-on (claims 7-8) is unlikely to be novelty
Claim 7 and 8 broadly list standard immunosuppressants used in autoimmune therapy. Even if those combinations are used in the specification, claim validity often relies on the IL-2 mutein/Treg process, not on the background immunosuppressant list. If the ex vivo Treg method is weak against prior art, adding a known immunosuppressant generally does not restore novelty unless a specific synergy or procedural requirement is claimed.
Claim-by-claim vulnerability and strength assessment
Claim 1 (independent): medium strength on “method steps,” medium-to-high vulnerability on “mutein position breadth”
- Strength: explicit process: PBMC contact → Treg-containing cell population → infusion → specified autoimmune diseases.
- Vulnerability:
- “substitution in at least one of positions 20/88/126” can overlap many IL-2 engineering variants if those residue positions are common engineering hotspots.
- “regulatory T cells” could be met by diverse gating strategies; if prior art reports “Treg-like” or FOXP3+ populations, claim 1 can be hard to avoid.
Claim 3 (N88 variants): narrower, but likely to collide with any “N88x” IL-2 engineering prior work
- Covers N88R, N88G, N88I.
- If any earlier filings disclose N88R/G/I in IL-2 and use it for Treg expansion or therapy, claim 3 becomes a focal collision point.
Claim 5 (D20 variants): narrower and residue-specific
- Covers D20H, D20I, D20Y.
- If D20 substitutions appear in known IL-2 mutein batteries, this claim is a direct overlap risk.
- The “D200” text anomaly requires close reading in legal interpretation, but it does not broaden the claim as written; it may narrow or create interpretive issues rather than expanding.
Claim 6 (Q126L): residue-specific, possibly narrower
- Q126L is a single variant.
- If prior art includes Q126L in any context for immune bias or Treg therapy, the collision is binary: either the prior art anticipates or it does not.
Claim 4 (further conservative substitutions): creates a “halo” around the defined variants
- Once a substitution exists at 20/88/126, additional conservative changes anywhere else can keep the mutein inside claim 4.
- This is a standard claim-extension strategy that can increase infringement surface against “nearby” engineering variants that change stability or manufacturing while preserving functional class.
Claims 2, 7, 8: process logistics plus known concomitants
- Claim 2 is procedural.
- Claim 7-8 are broadly enumerative and typically not a differentiator unless the method requires a specific timing or procedural dependency not captured by claim language.
How to read this patent for enforcement and design-around
What products or workflows are most likely to infringe
The highest-probability infringement profile is:
- a therapeutic workflow that uses PBMCs ex vivo
- contacted with an hIL-2 mutein bearing at least one substitution at position 20, 88, or 126 (SEQ ID NO:1 numbering)
- produces a Treg-containing product
- reinfuses into a patient to treat type I diabetes, MS, or SLE
Practical design-around levers
The claim set points to three main avoidance routes:
- Residue avoidance
- Use muteins with no substitution at positions 20/88/126 (as numbered in SEQ ID NO:1).
- Or use muteins that change function via different residues while maintaining IL-2 activity.
- Process avoidance
- Avoid PBMC contact to generate a Treg-containing population for infusion.
- Use in vivo IL-2 mutein dosing rather than ex vivo PBMC reprogramming, unless the claim language is expanded by other claims not provided here.
- Outcome avoidance
- Avoid producing a population that “comprises regulatory T cells” under the patent’s intended definition.
- In practice, this is harder than residue avoidance because most Treg expansion strategies create mixed populations with Tregs.
Combination avoidance
- Changing concomitant immunosuppressant choices likely does not avoid claims 1-6 if the core IL-2 mutein/Treg/adoptive transfer process is used.
Patent landscape implications for investors and competitors
Competitive relevance
This patent is strategically positioned to capture:
- IL-2 engineering programs that include substitutions at 20/88/126, and
- “cell therapy manufacturing” competitors that commercialize ex vivo Treg generation using IL-2 variants.
Likely licensing posture
Given the breadth of claim 1 on “at least one of positions 20/88/126,” the owner can present a relatively straightforward infringement theory against near-identical PBMC/Treg/adoptive-transfer protocols using related IL-2 muteins. That tends to support:
- cross-licensing pressure on IL-2 variant developers, and
- licensing pressure on cell therapy vendors if they adopt ex vivo IL-2 mutein contact.
Key Takeaways
- US 10,086,046 claims an ex vivo PBMC contact workflow that generates a Treg-containing cell population using hIL-2 muteins with substitutions at positions 20, 88, and/or 126 (SEQ ID NO:1 numbering), followed by adoptive transfer to treat type I diabetes, multiple sclerosis, or SLE.
- The enforceability hinge sits on two elements: (i) whether an accused IL-2 mutein includes substitutions at the claimed residue positions and (ii) whether the resulting cell product “comprises regulatory T cells.”
- Dependent claims 3, 5, and 6 focus on specific N88 and D20 and Q126 variants; claim 4 expands coverage through conservative additional substitutions.
- Claims 7-8 add broad immunosuppressant options and are unlikely to create strong novelty by themselves.
- For design-around, residue avoidance (not using substitutions at 20/88/126 as numbered in SEQ ID NO:1) is the cleanest path; process avoidance (not ex vivo PBMC-driven Treg generation for infusion) is the next best.
FAQs
-
Does claim 1 require a specific substitution identity at positions 20, 88, or 126?
No. Claim 1 requires “an amino acid substitution” at at least one of those positions, with specific identities covered in dependent claims 3, 5, and 6.
-
Is the therapeutic target limited to the listed autoimmune diseases?
Yes. Claim 1 limits the indication to type I diabetes, multiple sclerosis, or SLE.
-
Can the first and second organisms be different patients?
Claim 2 allows the first and second organisms to be the same individual or individuals of the same species, leaving open homologous transfer within the same species framing.
-
Do claims 7-8 meaningfully constrain the IL-2 process?
No. They add optional immunosuppressants from a broad list; they do not narrow the core IL-2 mutein/Treg/adoptive transfer requirements in the claim text provided.
-
What is the most direct design-around lever?
Avoid hIL-2 muteins that include substitutions at positions 20, 88, or 126 as numbered in SEQ ID NO:1, and avoid the ex vivo PBMC-to-Treg population generation step for adoptive transfer.
References
[1] US Patent 10,086,046 (claim text provided in prompt).
More… ↓
⤷ Start Trial
|
